Department of Maternal, Child and Adolescent Health, School of Public Health, Anhui Medical University, Hefei, China.
Key Laboratory of Population Health Across Life Cycle (AHMU), MOE, Hefei, China.
PLoS One. 2020 Dec 2;15(12):e0242523. doi: 10.1371/journal.pone.0242523. eCollection 2020.
Sulfonamides are widely used to treat infectious diseases during pregnancy. However, the safety of maternal exposure to sulfonamides is controversial. This study aims to systematically review the available studies and examine the effect of maternal sulfonamides use on adverse pregnancy outcomes.
We searched PubMed, Science Direct, Web of Science, ClinicalTrials.gov, CNKI and Wanfang Database (in Chinese). The meta-analysis used random effects model or fixed effects model to obtain the total odds ratio (OR) for each outcome through Stata11.0 software. Study on the relationship between sulfonamide exposure during pregnancy and adverse pregnancy outcomes. The study design covered randomized controlled trials, cohort studies and case-control studies. The study protocol was registered in PROSPERO with protocol number CRD42020178687.
A total of 10 studies, and 1096350 participants were included for systematic review. Maternal exposure to sulfonamides was found to be possibly associated with increased risk of congenital malformations (OR = 1.21, 95% CI 1.07-1.37). The use of sulfonamides in the first trimester of pregnancy and during the entire pregnancy might be associated with congenital malformations.
Maternal exposure to sulfonamides may be associated with offspring' s congenital malformations. Prescription of sulfonamides for pregnant women is suggested to be carefully censored.
磺胺类药物在怀孕期间被广泛用于治疗传染病。然而,母体暴露于磺胺类药物的安全性存在争议。本研究旨在系统回顾现有研究,探讨母体磺胺类药物使用对不良妊娠结局的影响。
我们检索了 PubMed、Science Direct、Web of Science、ClinicalTrials.gov、中国知网(CNKI)和万方数据库(Wanfang Database)。Meta 分析使用随机效应模型或固定效应模型,通过 Stata11.0 软件获得每种结局的总优势比(OR)。研究磺胺类药物暴露与妊娠不良结局的关系。研究设计涵盖随机对照试验、队列研究和病例对照研究。研究方案已在 PROSPERO 中注册,注册号为 CRD42020178687。
共纳入 10 项研究,共计 1096350 名参与者进行系统评价。母体暴露于磺胺类药物可能与先天性畸形风险增加相关(OR=1.21,95%CI 1.07-1.37)。妊娠早期和整个孕期使用磺胺类药物可能与先天性畸形有关。
母体暴露于磺胺类药物可能与后代先天性畸形有关。建议谨慎审查孕妇使用磺胺类药物的处方。